RxDoctor Payments Data

Jonathan Lappen

Corneal and Contact Management · Pittsburgh, PANPI 1780847483

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 23 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by Johnson & Johnson Vision Care, Inc. at 38.3% of the total. Reporting peaked in 2024 at $317 and has fallen 81.2% since, to $60 in 2025.

$776in general payments, 2019–2025

Across 23 payments — averaging $33.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson Vision Care, Inc.$297
  • Coopervision Inc.$249
  • Alcon$83
  • LKC Technologies, Inc.$72
  • Biotissue Holdings Inc.$22
  • AbbVie$20
  • plus $32 from 2 others

What the payments were for

  • Food & beverage$776100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$776 in reported general payments places this provider in the 65th percentile of 43 corneal and contact management providers in Pennsylvania.

See all corneal and contact management providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$73,345
Medicare patients
367
Services billed
982

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine37$36,169
Cyclosporine40$33,131
LumiganBimatoprost62$26,915
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol53$7,848
Travoprost23$4,956
Latanoprost198$2,963
Brimonidine Tartrate40$1,482
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha87$853
Timolol Maleate37$408
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat13$233
Cephalexin23$106

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$20$63,08499 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 43 corneal and contact management providers in Pennsylvania.

Other corneal and contact management in Pittsburgh

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →